What is SonoMotion?
SonoMotion operates at the intersection of medical engineering and patient care, specializing in the design and manufacture of non-invasive solutions for the treatment of kidney stones. By prioritizing patient comfort and clinical efficacy, the company addresses a critical gap in the urological market, where traditional surgical interventions often involve significant recovery times and procedural risks. Its core technology platform is engineered to provide a scalable, efficient alternative that aligns with the global shift toward outpatient and minimally invasive healthcare delivery models. As a specialized player in the MedTech sector, SonoMotion is uniquely positioned to capitalize on the increasing demand for cost-effective, high-precision urological tools.
How much funding has SonoMotion raised?
SonoMotion has raised a total of $27.2M across 4 funding rounds:
Series A
$4.6M
Series B
$10M
Debt
$179K
Series C
$12.4M
Series A (2017): $4.6M, investors not publicly disclosed
Series B (2019): $10M, investors not publicly disclosed
Debt (2021): $179K supported by PPP
Series C (2022): $12.4M featuring Advanced MedTech Holdings
Key Investors in SonoMotion
Advanced MedTech Holdings
Advanced MedTech Holdings is a global leader in urological stone management and robotic surgery, backed by Temasek Holdings. The firm specializes in integrating innovative medical devices to transform urological care across more than 100 countries.
Undisclosed Investor
An institutional partner providing strategic capital to support the scaling of SonoMotion's non-invasive medical device portfolio.
PPP
Public-Private Partnership
What's next for SonoMotion?
With the successful closure of its latest funding round, SonoMotion is poised to enter a phase of aggressive commercialization and clinical validation. The strategic capital will likely be deployed to enhance manufacturing capabilities, support ongoing regulatory submissions, and broaden the reach of its non-invasive treatment modalities. As the company transitions from a development-focused entity to a commercial-stage enterprise, the focus will shift toward establishing robust distribution networks and deepening its integration within hospital systems. Future growth will be contingent upon the company's ability to maintain its technological edge while navigating the complex regulatory and reimbursement environments inherent to the global medical device industry.
See full SonoMotion company page
